
CEO of techbio company @kantify - AI against rare diseases and cancer
bruxelles
Joined January 2012
- Tweets1.4K
- Following1.4K
- Followers1.1K
- Likes2.9K
Ségolène Martin retweeted
Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism"
—the 1st human to undergo custom genome editing
—outgrowth of decades of NIH funded research
nejm.org/doi/full/10.1056/NE…
nejm.org/doi/full/10.1056/NE… @NEJM
nytimes.com/2025/05/15/healt…
Ségolène Martin retweeted
Have your say ! Call for evidence for the Biotech Act:
ec.europa.eu/info/law/better…
The biotech sector plays a critical role in several areas of the EU economy. It is research-driven, fast-moving and requires substantial public and private investments.
Ségolène Martin retweeted
Good news everyone! The unpopular and seemingly irrelevant lecture I give in my health econ class on "Most favored nations agreements" just became prophetically relevant.
Bad news everyone! This is a terrible policy.
🧵
Ségolène Martin retweeted
ANY foreign clinical trial site that's part of NIH-funded research may be forced to shut down under new 'America First'-driven policy: statnews.com/2025/05/02/nih-…
Ségolène Martin retweeted
The NeurIPS 2025 Creative AI Track is now inviting research papers and artworks that explore cutting edge applications of AI and ML in art, design, and creative practice. This year, we welcome submissions on the theme of "Humanity".
Read more in our Call for Creative AI 2025:
neurips.cc/Conferences/2025/…
Ségolène Martin retweeted
3. Rare Disease (cited 15 and 72 patients worldwide for example) may get approval based on mechanism of action only - then track and follow patients to see if drug works.
Ségolène Martin retweeted
A smart foreign-born undergrad at a US university asked me if he should go to the UK to start his startup because of the random deportations here. I said that while the median startup wasn't taking things to this extreme yet, it would be an advantage in recruiting.
Ségolène Martin retweeted
No! This photo is not AI edited: a heart-shaped sun ray appeared right during our last team photo!❤️
Meet below a team of people working every day with a lot of ❤️, talent, and AI - to accelerate the discovery of therapies for patients who need them the most.
Ségolène Martin retweeted
Today, we at OpenAI launched Deep Researcher and I wanted to share a deeply personal story about how amazing this tool is and how it will change the world. Trigger warning, related to cancer....1/9
Ségolène Martin retweeted
Hey Twitter, we are disclosing our biotech pipeline, and there is even a bonus for drug discovery experts.
Cancer, Rare Cancers, Rare Neuromuscular disorders, Neurology and Ion Channels are some of our areas of focus.
Ségolène Martin retweeted
Can an AI for human drug discovery also excel in plant drug discovery? The answer is yes!
This is what our COO @Nico_Maignan explained at his lecture "Unlocking & Accelerating Drug Discovery with Artificial Intelligence: The Kantify Approach." held by our partner @IBMCP 🙏🌿
Ségolène Martin retweeted
Scared to share this after 10 freaking years of waiting but here we go: We found that temperature *perception* can change the next generations, even when “it’s just in the parents' head”. Read how C. elegans neurons control epigenetic inheritance! biorxiv.org/content/10.1101/…
Ségolène Martin retweeted
Today, we're unveiling the latest small molecule drug screened by our AI, Sapian.
Many of you are familiar with this medication-it was the 169th most prescribed drug in the United States in 2022, with over 3 million prescriptions.
This widely used drug is Diazepam, aka Valium.
Ségolène Martin retweeted
Full house today at Science For Health where we were proud to showcase our AI technology Sapian!
1/n
Ségolène Martin retweeted
BREAKING NEWS
The 2024 #NobelPrize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.
Ségolène Martin retweeted
Mario Draghi's new report on EU competitiveness doesn't mince words.
"Across different metrics, a wide gap in GDP has opened up between the EU and the US, driven mainly by a more pronounced slowdown in productivity growth in Europe. Europe’s households have paid the price in foregone living standards. On a per capita basis, real disposable income has grown almost twice as much in the US as in the EU since 2000."
"First – and most importantly – Europe must profoundly refocus its collective efforts on closing the innovation gap with the US and China, especially in advanced technologies. Europe is stuck in a static industrial structure with few new companies rising up to disrupt existing industries or develop new growth engines. In fact, there is no EU company with a market capitalisation over EUR 100 billion that has been set up from scratch in the last fifty years, while all six US companies with a valuation above EUR 1 trillion have been created in this period. This lack of dynamism is self-fulfilling."
"There are not enough academic institutions achieving top levels of excellence and the pipeline from innovation into commercialisation is weak. [...] However, while the EU boasts a strong university system on average, not enough universities and research institutions are at the top. Using volume of publications in top academic science journals as an indicative metric, the EU has only three research institutions ranked among the top 50 globally, whereas the US has 21 and China 15."
"Regulatory barriers to scaling up are particularly onerous in the tech sector, especially for young companies. Regulatory barriers constrain growth in several ways. First, complex and costly procedures across fragmented national systems discourage inventors from filing Intellectual Property Rights (IPRs), hindering young companies from leveraging the Single Market. Second, the EU’s regulatory stance towards tech companies hampers innovation: the EU now has around 100 tech-focused laws and over 270 regulators active in digital networks across all Member States. Many EU laws take a precautionary approach, dictating specific business practices ex ante to avert potential risks ex post. For example, the AI Act imposes additional regulatory requirements on general purpose AI models that exceed a pre-defined threshold of computational power – a threshold which some state-of-the-art models already exceed. Third, digital companies are deterred from doing business across the EU via subsidiaries, as they face heterogeneous requirements, a proliferation of regulatory agencies and “gold plating” of EU legislation by national authorities. Fourth, limitations on data storing and processing create high compliance costs and hinder the creation of large, integrated data sets for training AI models. This fragmentation puts EU companies at a disadvantage relative to the US, which relies on the private sector to build vast data sets, and China, which can leverage its central institutions for data aggregation. This problem is compounded by EU competition enforcement possibly inhibiting intra-industry cooperation. Finally, multiple different national rules in public procurement generate high ongoing costs for cloud providers. The net effect of this burden of regulation is that only larger companies – which are often non-EU based – have the financial capacity and incentive to bear the costs of complying. Young innovative tech companies may choose not to operate in the EU at all."
More: commission.europa.eu/documen….
Dear Mario Draghi, a year ago, I asked you to prepare a report on the future of Europe’s competitiveness.
No one was better placed than you to take up this challenge.
Now, we are eager to listen to your views ↓
nitter.gq/i/broadcasts/1mnxeAPOD…
Ségolène Martin retweeted
Curious about how #AI is transforming drug discovery?
@Kantify, co-leading @DreamsPjt_EU with @IStemFrance, is leveraging its AI expertise to discover treatments for neuromuscular disorders and enhance efficiency.
Check out @Segozone's insights 📽️: youtube.com/watch?v=sA3QAO70…
























